

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 December 2010 (23.12.2010)

PCT

(10) International Publication Number  
**WO 2010/145903 A1**

(51) International Patent Classification:

*A61K 31/593* (2006.01)    *A61P 3/08* (2006.01)  
*A61P 3/02* (2006.01)    *A61P 13/08* (2006.01)  
*A61P 19/10* (2006.01)    *A61P 35/00* (2006.01)  
*A61P 17/06* (2006.01)    *A61P 5/18* (2006.01)

(21) International Application Number:

PCT/EP2010/056832

(22) International Filing Date:

18 May 2010 (18.05.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/179,906    20 May 2009 (20.05.2009)    US

(71) Applicant (for all designated States except US): **HYBRI-GENICS SA** [FR/FR]; 3/5 Impasse Reille, F-75014 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DELANSORNE, Rémi** [FR/FR]; 30, rue Guynemer, F-75006 Paris (FR).  
**DUFOUR-LAMARTINIE, Jean-François** [FR/FR]; 132, rue de la Roquette, F-75011 Paris (FR).

(74) Agents: **JACOBSON, Claude** et al.; Cabinet LAVOIX, 2 Place d'Estienne d'Orves, F-75441 Paris Cedex 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NEW THERAPEUTICAL USES OF INECALCITOL

(57) Abstract: The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof.




WO 2010/145903 A1

## NEW THERAPEUTICAL USES OF INECALCITOL

Vitamin D is a group of prohormones, the two major forms of which are vitamin D<sub>2</sub> (or ergocalciferol) and vitamin D<sub>3</sub> (or cholecalciferol). Vitamin D, its metabolites and analogues have potent effects on calcium and phosphate metabolism and can therefore be used for prevention and therapy of vitamin D deficiency, such as rickets, and other disorders of plasma and bone mineral homeostasis such as osteoporosis and osteomalacia. Moreover, vitamin D receptors and vitamin D activity have also been documented in numerous other tissues and cells, where they are also known to be involved in cell proliferation and differentiation. Vitamin D also affects the immune system as vitamin D receptors are expressed in several white blood cells including monocytes, macrophages and T and B lymphocytes.

These so-called non-calcemic effects of vitamin D lead to consider the possible use of vitamin D derivatives for various therapeutic applications such as disorders of the immune system, hormone secretion, cell differentiation or cell proliferation. In particular, such compounds may be useful in the therapy of disorders characterized by increased cell proliferation, such as psoriasis and/or cancer. In particular, 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub>, the active metabolite of vitamin D<sub>3</sub> named calcitriol, is known to inhibit the proliferation of many cancer cells lines of various origins *in vitro* and to slow the progression of various tumor xenografts *in vivo*. The major drawback related to the use of this compound is its hypercalcemic effect, which prevents the application of pharmacologically active doses. The toxic effects of calcitriol and all vitamin D analogues are the consequences of hypercalcemia leading to micro-crystallization of calcium in various tissues, or inducing disorders of muscle contractility. Hypercalcemia may thus cause death by impairing contraction of the heart (cardiac arrest) or by accumulation of calcium micro-crystals in renal tubules (kidney failure). Hypercalcemia may also cause arthritis or cataract (deposits of micro-crystals in the joints or in the eye lens, respectively) or muscle weakness (impaired contractions). It is therefore of utmost importance for a vitamin D analogue to be used in therapeutics without the risk of inducing hypercalcemia.

A large number of analogues of calcitriol displaying a clear dissociation between anti-proliferative and calcemic effects have been reported. In particular, EP 0 707 566 B1 discloses a number of calcitriol analogues such as 14-epianalogues. Among these 14-epianalogues of calcitriol is inecalcitol of formula:



Inecalcitol is the international non-proprietary name for 19-nor-9,10-seco-14βH-cholesta-5(Z),7(E)-dien-23-ino-1α,3β,25-triol-23-yne (C<sub>26</sub>H<sub>40</sub>O<sub>3</sub>).

Inecalcitol is a synthetic derivative of calcitriol, the natural active metabolite of vitamin D<sub>3</sub>. Eelen et al. (Molecular Pharmacology 67, 1566-1573, 2005) and Verlinden et al (Journal of Bone and Mineral Research, volume 16(4), 625-638, 2001) showed the enhanced antiproliferative and markedly lower calcemic effects of inecalcitol compared with calcitriol. Verlinden et al. (Cancer Research 60(10), 2673-2679, 2000) also reported the *in vitro* and *in vivo* activity of inecalcitol in inhibiting the growth of human breast cancer cells. This profile has positioned inecalcitol as an effective drug candidate, initially for the treatment cancer.

Considering the hypercalcemic effect of vitamin D and its analogues, it has been common practice to administer low doses of these compounds, or frequency of administration lower than once a day. As a result, vitamin D or its analogues are administered at doses generally much lower than 200 µg/day, and often every other day or once a week. In particular, the approved dose of calcitriol for vitamin D deficiency is 0.25 or 0.5 µg/day and the tested dose for calcitriol in cancer clinical trial was 45 µg/patient once a week; in the case of seocalcitol, the tested dose in cancer clinical trials was 10 µg/day/patient; for elocalcitol in clinical trials for benign prostate hyperplasia, the tested dose was 150 µg/day/patient; for the treatment of hypersecretion of parathormone (hyperparathyroidism), paricalcitol is approved at the maximum dosage of 2 µg/day or 4 µg every other day, and doxercalciferol at the maximum dosage of 3.5 µg/day or 20 µg every other day.

It is thus desirable to provide derivatives of vitamin D which are less toxic and can thus be administered at high pharmacologically active doses.

EP 0 707 566 B1 merely mentions a vitamin D analogue dose of 0.1 to 500  $\mu\text{g/g}$  relative to the weight of the topical formulation to be applied on the skin to treat psoriasis. Verlinden et al (Cancer Research, supra) merely mentioned an inecalcitol dose of 80  $\mu\text{g/kg}$ /every other day for administration in mice and are silent in respect of administration in human patients.

Further, in order to achieve the highest possible therapeutic effect from the active ingredient, it is desirable to increase the administered doses, without inducing side effects, such as hypercalcemia with all its deleterious consequences described above.

It has now been surprisingly discovered that inecalcitol was devoid of hypercalcemic effect at doses generally considered to be too toxic for all other known vitamin D analogues.

The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease, in particular cancer, comprising administering inecalcitol at doses comprised between 1 mg and 100 mg to a human or animal patient in need thereof.

The present invention also concerns inecalcitol for use for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease, in particular cancer, for administration at doses comprised between 1 mg and 100 mg to a human or animal patient in need thereof.

Said administration dose is preferably comprised between 1.5 mg and 20 mg.

According to a preferred embodiment, the method of the invention comprises administering inecalcitol at doses comprised between 1.5 mg and 20 mg for the treatment and/or prevention of the above disorders, particularly any type of cancer, without inducing increased calcemia in the treated patient.

According to another embodiment, the method of the invention may comprise the administration of said doses of inecalcitol, at a frequency comprised between every three days up to three times a day, such as every three days, every other day (qod), once-a-day (qd), twice-a-day (bid) or three times a day (tid). Preferably, the administration may take place every other day, once a day or twice-a-day.

According to a further embodiment, the method of the invention also comprises the administration of one or more further active ingredient, selected from anti-osteoporotic agents, immunomodulatory agents, anti-inflammatory agents, anti-psoriatic agents, anti-hormonal agents, antiproliferative agents or anti-cancer agents.

Preferably, said anti-cancer agent is chosen from taxoid derivatives, in particular paclitaxel or docetaxel, or a platinum derivative in particular carboplatin, oxaliplatin or satraplatin. Said administration may be simultaneous, separate or sequential with that of inecalcitol.

According to another embodiment, the method of the invention is to treat various forms of cancers, including tumors or leukemia. Cancers of breast, prostate, lung, colon, bladder, brain, stomach, kidney, liver, ovary, mouth, skin, intestine, uterine, head and neck, throat and blood cancers are encompassed herein, particularly prostate cancer.

According to another embodiment, the method of the invention is to treat non-cancerous hyperproliferative disorders of the skin, particularly psoriasis, by administration of inecalcitol at high dose, alone or in combination with systemic oral or parenteral treatments of psoriasis on the market or in development such as acitretine and retinoids in general, cyclosporine, voclosporine, sirolimus, tacrolimus, methotrexate and immunosuppressants or immunomodulators in

general, alefacept, etanercept, infliximab adalimumab, certolizumab, golimumab and anti-Tumor Necrosis Factor-alpha therapeutics in general, ustekinumab, briakinumab and anti-interleukines therapeutics in general, apremilast, MAP Kinase inhibitors, A3 adenosine agonists, and the like (Melnikova, Nature reviews drug discovery 2009, 8, 767-768).

According to another embodiment, the method of the invention is to treat the symptoms, prevent relapses or prolong remissions of multiple sclerosis, by administration of inecalcitol at high dose, alone or in combination with systemic oral or parenteral treatments of multiple sclerosis on the market or in development such as interferons alpha and beta and their various isoforms, mitoxantrone, laquinimod, fingolimod and immunosuppressants or immunomodulators in general, natalizumab, daclizumab, copaxone, cladribine, teriflunomide, and the like.

Inecalcitol may be preferably administered by oral route.

According to another object, the present invention also relates to the above-mentioned therapeutic treatment methods comprising the administration of inecalcitol with a pharmaceutically acceptable carrier or excipient to a patient in the need thereof.

When used herein, inecalcitol refers to inecalcitol or its pharmaceutically acceptable salts thereof.

The identification of those subjects who are in need of treatment of herein-described diseases and conditions is well within the ability and knowledge of one skilled in the art. A clinician skilled in the art can readily identify, by the use of clinical tests, physical examination, genetic tests and medical/family history, those subjects who are in need of such treatment.

A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of subject; its size, age, and general health; the specific disease involved; the degree of involvement or the

severity of the disease; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

The amount of inecalcitol, which is required to achieve the desired biological effect, will vary depending upon a number of factors, including the dosage of the drug to be administered, the type of disease, the disease state of the patient and the route of administration.

“Pharmaceutically” or “pharmaceutically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.

As used herein, “pharmaceutically acceptable carrier” includes any diluents, adjuvants, excipients, or vehicles. The use of such carriers for pharmaceutical active substances is well known in the art.

In the context of the invention, the term “treating” or “treatment”, as used herein, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.

“Therapeutically effective amount” means an amount of a compound/medicament according to the present invention effective in producing the desired therapeutic effect.

According to the invention, the term “patient”, or “patient in need thereof”, is intended for a human or non-human mammal affected or likely to be affected with rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease. Preferably, the patient is a human.

In general terms, the preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration and will generally exceed 1 mg/day per patient.

Inecalcitol is capable of being administered in unit dose forms, wherein the term "unit dose" means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition.

Inecalcitol can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.

The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in *Remington: The Science and Practice of Pharmacy*, 20<sup>th</sup> ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000. The usual unit doses for oral administration of vitamin D analogues are soft gelatine capsules containing medium chain triglycerides from fractionated coconut oil in which the compound is dissolved like for calcitriol, doxercalciferol or paricalcitol.

Figure 1 illustrates the mean plasma concentrations vs time obtained during a 9-month toxicology study on once-a-day oral inecalcitol performed in male mature monkeys.

Figure 2 illustrates the mean plasma concentrations vs time obtained during a 2-week toxicology study on twice-a-day oral inecalcitol performed in male juvenile monkeys.

Figure 3 illustrates the mean pharmacokinetic profiles obtained with 300, 600 and 1000 µg of oral inecalcitol administered to human patients.

Figure 4 illustrates the mean pharmacokinetic profiles obtained with 2 and 4 mg of oral inecalcitol administered to human patients

The following examples are given as representative non-limiting illustrations of the invention.

#### **Example 1 : 9-month toxicology and toxicokinetic study of once-a-day oral inecalcitol in monkeys**

During a 9-month toxicology study in male mature cynomolgus monkeys by daily oral administration of inecalcitol, no hypercalcemia and no toxic effects were observed, even at the highest tested dose of 1.8 milligram (mg) per day per



monkey, despite a consistently high peak exposure to inecalcitol in blood. On figure 1, mean plasma concentrations of inecalcitol are plotted vs. time on the first day of the study and close to its end, at day 272. The mean toxicokinetic profiles are almost superimposable, with a mean peak of about 1.2 ng/ml achieved as soon as 15 minutes after oral intake, and a steady disappearance from circulation within 4 hours. Higher doses, not tested in the study, may also be devoid of hypercalcemia and of toxic effects since the maximal tolerated dose has not been reached. In the table below, plasma calcium levels (in mmoles/L, mean  $\pm$  s.e.m.) at different time points during the study did not show any difference between control and treated monkeys.

Study Day	Day -12	Day 85	Day 175	Day 268
Controls (n = 6)	2.48 $\pm$ 0.02	2.59 $\pm$ 0.06	2.46 $\pm$ 0.05	2.53 $\pm$ 0.03
Treated (n = 6)	2.54 $\pm$ 0.11	2.53 $\pm$ 0.03	2.49 $\pm$ 0.05	2.51 $\pm$ 0.05

### **Example 2 : 2-week toxicology and toxicokinetic study of twice-a-day oral inecalcitol in monkeys**

During a 2-week toxicology study in male juvenile cynomolgus monkeys by twice daily oral administrations of inecalcitol, no hypercalcemia and no toxic effects were observed at the dosage of 2 x 1.6 milligram (mg) each day, despite a frequent exposure to very high plasma levels of inecalcitol. On figure 2, mean plasma concentrations of inecalcitol are plotted vs. time on the first day of treatment with two successive administrations of inecalcitol around 8 AM and 7 PM, i.e. about 11 hours apart. Two almost identical peaks were observed reaching 2.75 ng/ml and 2.50 ng/ml respectively. In both instances, inecalcitol levels returned to basal levels within 4 hours. In the table below, plasma calcium levels (in mmoles/L, mean  $\pm$  s.e.m.) were monitored in the same 4 animals for two weeks before and for two weeks during the treatment period. No significant changes in plasma calcium were observed.

Study Day	Day -13	Day -6	Day 7	Day 13
Plasma Ca	2.66 $\pm$ 0.08	2.61 $\pm$ 0.06	2.68 $\pm$ 0.15	2.76 $\pm$ 0.12

**Example 3: Dose finding and clinical tolerance study of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients****3.1 Methods**

Escalating oral dosages of inecalcitol were combined to chemotherapy in naive HRPC patients. Safety was evaluated in groups of 3-6 patients receiving inecalcitol every other day (qod) or daily (qd) on a 21-day cycle in combination with intravenous docetaxel (75mg/m<sup>2</sup> q3w) and oral prednisone (5 mg bid). Patients (pts) received up to six cycles unless unacceptable toxicity or disease progression. Primary endpoint was dose limiting toxicity (DLT) defined as grade 3 hypercalcemia within the first cycle. Calcemia, creatininemia and complete blood counts were assessed weekly; biochemistry, electrocardiogram and prostate specific antigen (PSA) every 3 weeks. Efficacy endpoint was PSA response defined as  $\geq 30\%$  decline within 3 months.

Inecalcitol was given to patients in soft gelatine capsules of different sizes, shapes and strengths depending on the dose level studied: one, two or four 40  $\mu$ g capsules (size 11, oblong shape) for administration of 40, 80 or 160  $\mu$ g/day, respectively; three or six 100  $\mu$ g capsules (size 4, round shape) for administration of 300 or 600  $\mu$ g/day, respectively; five 200  $\mu$ g capsules (size 7.5, oval shape) for administration of 1,000  $\mu$ g/day; five 400  $\mu$ g capsules (size 14, oblong shape) for administration of 2 mg/day, and four 1 mg capsules (size 14, oblong shape) for administration of 4 mg/day. In all the capsules, inecalcitol was present in the fill content as a solution in medium chain triglycerides from fractionated coconut oil at different concentrations depending on the capsule strengths.

**3.2 Clinical results**

Eight dose levels: 40  $\mu$ g (qd), 80  $\mu$ g (qod,qd), 160  $\mu$ g (qod,qd), 300  $\mu$ g (qod,qd), 600  $\mu$ g (qod,qd), 1,000  $\mu$ g (qod,qd), 2 mg (qd) and 4 mg (qd) have been evaluated; 50 pts have been treated; 47 pts have completed 6 cycles. Median age was 71 years [range, 49-87], median Gleason score (Gs) 7 and median PSA 35.7

ng/mL [range, 0.9-962.4]. No increased calcemia was reported. Most adverse events (AE) were G1-2, asthenia (22 pts), constipation (15 pts), diarrhea (13 pts). G3-4 AEs were neutropenia (36 pts) lymphopenia (12 pts), asthenia (3pts), arrhythmia (2 pts), general health deterioration (3 pts) and diarrhea (1 pt). All these AEs were related to docetaxel and none to inecalcitol. Of the 42 evaluable pts for PSA response within three months of treatment, 35 (83%) showed a PSA decline of more than 30%.

### **3.3. Pharmacokinetics of inecalcitol in HRPC patients**

Oral administration of inecalcitol at doses of 300 µg (qod,qd), 600 µg (qod,qd), 1000 µg (qod,qd), 2 mg (qd) or 4 mg (qd) to human hormone-refractory prostate cancer patients did not induce any hypercalcemia or any toxic effect. Figure 3 shows the mean pharmacokinetic profiles obtained at the first three dose levels of 300, 600 and 1000 µg. Inecalcitol was assayed as unchanged circulating compound in the plasma by liquid chromatography followed by tandem mass spectrometry (LC/MS/MS). At 300 µg, peak values are barely detectable above the lower limit of quantitation achieved by the LC/MS/MS method, i.e. 10 pg/ml (0.01 ng/ml). At 600 µg and 1000 µg, mean peak values reached around 35 and 45 pg/ml (0.035 and 0.045 ng/ml) at 90 and 45 minutes, respectively. Figure 4 shows the mean pharmacokinetic profiles with 2 mg and 4 mg of inecalcitol: mean peak values reached around 70 and 260 pg/ml (0.07 and 0.26 ng/ml) at 90 and 45 minutes respectively. In the four mean pharmacokinetic profiles obtained between 600 µg and 4 mg, the disappearance of inecalcitol was regular with an approximate half-life comprised between 1 and 1.5 hour.

CLAIMS

1. Inecalcitol for use for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease, at doses comprised between 1 mg and 100 mg.

2. Inecalcitol for the use according to claim 1 wherein said administration dose is comprised between 1.5 mg and 20 mg.

3. Inecalcitol for the use according to claim 1 or 2 which does not simultaneously induce increased calcemia in the treated patient.

4. Inecalcitol for the use according to anyone of claims 1 to 3 which comprises the administration of said doses of inecalcitol, at a frequency chosen from every three days, every other day (qod), once-a-day (qd), twice-a-day (bid) and three times a day (tid).

5. Inecalcitol for the use according to anyone of claims 1 to 4 wherein the administration is at a frequency chosen from every other day, once a day and twice a day.

6. Inecalcitol for the use according to anyone of claims 1 to 5 which also comprises the administration of one or more further active ingredient selected from anti-osteoporotic agents, immunomodulatory agents, anti-inflammatory agents, anti-psoriatic agents, anti-hormonal agents, antiproliferative agents and anti-cancer agents.

7. Inecalcitol for the use according to claim 6 wherein said further administration(s) is (are) simultaneous, separate or sequential with that of inecalcitol.

8. Inecalcitol for the use according to anyone of claims 1 to 7 which is for treating cancers, tumours or leukemia.

9. Inecalcitol for the use according to anyone of claims 1 to 8 wherein inecalcitol is administered by oral route.


10. Inecalcitol for the use according to anyone of claims 1 to 9 which is for treating psoriasis.

11. Inecalcitol for the use according to anyone of claims 1 to 10 which is for treating multiple sclerosis.

12. Inecalcitol for the use according to anyone of claims 1 to 11 which is for treating for treating hyperparathyroidism.


13. Inecalcitol for the use according to anyone of claims 1 to 12 which is for treating benign prostate hyperplasia.

**Pharmacokinetics of inecalcitol in male monkeys  
daily treated orally with 1.8 mg for 272 days**




**FIG.1**

**FIG.2**




Pharmacokinetics of oral inecalcitol  
in hormone-refractory prostate cancer patients



**FIG.3**





# INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/056832

## A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/593 A61P3/02 A61P19/10 A61P17/06 A61P3/08  
A61P13/08 A61P35/00 A61P5/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, EMBASE, BIOSIS, FSTA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
-----------	--	-----------------------

X	<p>Hybrigenics: "Promising interim results from Hybrigenics' Inecalcitol Phase II in combination with Taxotere(R) for hormone refractory prostate cancer"[Online] 19 April 2009 (2009-04-19), XP002592440 Medical News Today Retrieved from the Internet: URL: <a href="http://www.medicalnewstoday.com/articles/146552.php">http://www.medicalnewstoday.com/articles/146552.php</a> [retrieved on 2010-07-08]</p>	1,3-9
Y	<p>the whole document</p> <p style="text-align: center;">----- -/--</p>	10

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 July 2010

Date of mailing of the international search report

09/08/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Estañol, Inma

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/056832

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>EELLEN GUY ET AL: "Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction" MOLECULAR PHARMACOLOGY, vol. 67, no. 5, May 2005 (2005-05), pages 1566-1573, XP002592441 ISSN: 0026-895X the whole document</p>	1-8
Y	<p>VERLINDEN LIEVE ET AL: "Two novel 14-epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo" CANCER RESEARCH, vol. 60, no. 10, 15 May 2000 (2000-05-15), pages 2673-2679, XP002592442 ISSN: 0008-5472 the whole document</p>	1-8
Y	<p>EP 0 972 762 A2 (THERAMEX [MC]) 19 January 2000 (2000-01-19) paragraph [0057] - paragraph [0066]; claims 1-19</p>	1-12
Y	<p>EELLEN GUY ET AL: "Vitamin D analogs and coactivators" ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 26, no. 4A, 1 July 2006 (2006-07-01), pages 2717-2721, XP009135948 ISSN: 0250-7005 page 2719 - page 2720</p>	1-12
Y	<p>Anonymous: "Hybrigenics in-licences Merk KGaA's inecalcitol"[Online] 8 February 2006 (2006-02-08), XP002592443 Biocentury Retrieved from the Internet: URL: <a href="http://www.biocentury.com/dailynews/company/2006-02-08/hybrigenics-in-licenses-merck-kgaas-inecalcitol">http://www.biocentury.com/dailynews/company/2006-02-08/hybrigenics-in-licenses-merck-kgaas-inecalcitol</a> [retrieved on 2010-07-09] the whole document</p>	10

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

International application No

PCT/EP2010/056832

Patent document cited in search report		Publication date		Patent family member(s)		Publication date	
EP 0972762	A2	19-01-2000	EP GR	0707566 A1 3033856 T3		24-04-1996 31-10-2000	
<hr/>							